Athenex, Inc. Announces Proposed Public Offering of Common Stock
September 08 2020 - 4:01PM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer, today announced that
it intends to offer and sell, subject to market conditions,
10,000,000 shares of its common stock in an underwritten public
offering. In addition, Athenex expects to grant the underwriters a
30-day option to purchase up to an additional 1,500,000 shares of
common stock at the public offering price, less underwriting
discounts and commissions. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
SVB Leerink, RBC Capital Markets and Evercore ISI
are acting as joint book-running managers and Oppenheimer & Co.
is acting as lead manager for the offering.
The securities described above are being offered by
Athenex pursuant to a shelf registration statement on Form S-3
(File No. 333-227492) that was filed with the Securities and
Exchange Commission (the “SEC”) on September 24, 2018 and became
effective upon filing. A preliminary prospectus supplement relating
to and describing the terms of the offering will be filed with the
SEC and will be available on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering, when available,
may be obtained from: SVB Leerink LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, by
telephone at 1-800-808-7525, ext. 6218, or by email at
syndicate@svbleerink.com; RBC Capital Markets, LLC, Attention:
Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281,
by telephone at (877) 822-4089, or by email at
equityprospectus@rbccm.com; and Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York,
New York 10055, or by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy these securities, nor
shall there by any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage biopharmaceutical
company dedicated to becoming a leader in the discovery,
development and commercialization of next generation drugs for the
treatment of cancer. Athenex is organized around three platforms,
including an Oncology Innovation Platform, a Commercial Platform
and a Global Supply Chain Platform. The Company’s current clinical
pipeline is derived from four different platform technologies: (1)
Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase
inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4)
Arginine deprivation therapy. Athenex’s employees worldwide are
dedicated to improving the lives of cancer patients by creating
more active and tolerable treatments. Athenex has offices in
Buffalo and Clarence, New York; Cranford, New Jersey; Houston,
Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple
locations in Chongqing, China; Manchester, UK; Guatemala City,
Guatemala and Buenos Aires, Argentina.
Forward Looking StatementsExcept
for historical information, all of the statements, expectations,
and assumptions contained in this press release are forward-looking
statements. These forward-looking statements are typically
identified by terms such as “anticipate,” “believe,” “consider,”
“continue,” “could,” “estimate,” “expect,” “explore,” “foresee,”
“goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,”
“predict,” “preliminary,” “probable,” “project,” “promising,”
“seek,” “should,” “will,” “would,” and similar expressions. Actual
results might differ materially from those explicit or implicit in
the forward-looking statements. Important factors that could cause
actual results to differ materially include: the development stage
of our primary clinical candidates and related risks involved in
drug development, clinical trials, regulation, manufacturing and
commercialization; our ability to obtain and maintain regulatory
approvals for our product candidates; our reliance on third parties
for success in certain areas of Athenex’s business; our history of
operating losses and need to raise additional capital to continue
as a going concern; uncertainties around our ability to meet
funding conditions under our financing agreements and access to
capital thereunder; risks and uncertainties related to the COVID-19
pandemic and its potential impact on our operations, cash flow and
financial condition; our ability to integrate acquired assets and
businesses into our existing operations; competition; intellectual
property risks; risks relating to doing business internationally
and in China; the risk of production slowdowns or stoppages or
other interruptions at our Chongqing facilities; and the other risk
factors set forth from time to time in our SEC filings. All
information provided in this release is as of the date hereof and
we assume no obligation and do not intend to update these
forward-looking statements, except as required by law.
ContactsDaniel Lang, MD Corporate
Development and Corporate Communications
Email: danlang@athenex.com
Jacqueline LiCorporate Development and Investor
RelationsEmail: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024